Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsLTS:0J2O -1.39%88 EV-to-EBITDA is 20.07 as of Sep. 08, 2026, which is 31% above its 10-year median of 15.33. GuruFocus rates LTS:0J2O with a GF Score™ of 88/100 and a GF Value™ of $98.94 (Fairly Valued). The stock has 5 warning signs investors should review. Among 400 Biotechnology companies, Halozyme Therapeutics ranks worse than 58.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Halozyme Therapeutics's enterprise value is $14,422 Mil.
Halozyme Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $718 Mil. Therefore, Halozyme Therapeutics's EV-to-EBITDA for today is 20.07.
The historical rank and industry rank for Halozyme Therapeutics's EV-to-EBITDA or its related term are showing as below:
LTS:0J2O'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -202.34 Med: 15.33 Max: 139.02
Current: 20.08
During the past 13 years, the highest EV-to-EBITDA of Halozyme Therapeutics was 139.02. The lowest was -202.34. And the median was 15.33.
LTS:0J2O's EV-to-EBITDA is ranked worse than 58.25% of 400
companies
in the Biotechnology industry
Industry Median: 13.725
vs LTS:0J2O: 20.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Halozyme Therapeutics's PE Ratio (TTM) for today is calculated as:
Halozyme Therapeutics's share price for today is $108.74.
Halozyme Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Halozyme Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0J2O vs ARWR, CORT, MDGL: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's EV-to-EBITDA falls into.
Halozyme Therapeutics's current Enterprise Value is $14,422 Mil.
Halozyme Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $718 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (LTS:0J2O) has a EV-to-EBITDA of 20.07 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Halozyme Therapeutics. This is 31% above median its historical median of 15.33. According to the industry distribution chart, Halozyme Therapeutics ranks #233 out of 400 companies in the Biotechnology industry, placing it in the top 58.2%.
Is Halozyme Therapeutics' EV-to-EBITDA too high?
Halozyme Therapeutics' current EV-to-EBITDA of 20.07 is 31% above median its 10-year median of 15.33. The Biotechnology industry median EV-to-EBITDA is 13.73. Halozyme Therapeutics' value of 20.07 is 46.2% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #233 out of 400 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' EV-to-EBITDA compare to ARWR and CORT?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #233 out of 400 companies for EV-to-EBITDA. This places Halozyme Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.73. Halozyme Therapeutics' value of 20.07 is 46.2% above this benchmark. While the company's 10-year median is 15.33 vs. the industry median of 13.73, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.73, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current EV-to-EBITDA of 20.07 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Halozyme Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current EV-to-EBITDA is 20.07, which is 31% above median its own 10-year median of 15.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (LTS:0J2O) is currently considered Fairly Valued. The stock's GF Value™ is $98.94, compared to a current price of $108.74 — trading 9.9% above its estimated fair value. The current EV-to-EBITDA is 20.07, which is 31% above median its 10-year median of 15.33 and 46.2% above the Biotechnology industry median of 13.73. Halozyme Therapeutics' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Halozyme Therapeutics (LTS:0J2O), the current EV-to-EBITDA is 20.07 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (LTS:0J2O) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of $108.74 is trading 9.9% above its estimated GF Value™ of $98.94.
GuruFocus considers Halozyme Therapeutics to be Fairly Valued.
Key valuation signals for LTS:0J2O:
EV-to-EBITDA: 20.07 (31% above median its 10-year median of 15.33)
GF Value™: $98.94 vs. price of $108.74 (9.9% above fair value)
Industry Position: 46.2% above the Biotechnology median (#233 of 400)
No single metric tells the full story. See the LTS:0J2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
88GF Score
Get the complete analysis for LTS:0J2O
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0J2O has been successfully added to your 
